论文部分内容阅读
Most inhibitors target the highly conserved catalytic pocket of proteins,and as such often lead to potential side effects.For example,cyclin-dependent kinases(CDKs)are critical to the cell cycle and many other biological processes,and as such,are considered as one of the promising targets for therapy against cancer and other diseases.Most pan-CDK inhibitors bind to the highly conserved catalytic ATP-binding pocket and therefore lack the specificity to prevent side effects.It is thus highly desirable to develop non-catalytic inhibitors that inhibit activity via allosteric interactions.Here we performed a systematic analysis of pockets to identify the potential non-catalytic pockets via allosteric interactions.This approach of non-catalytic pocket identification can be an enabling tool for drug design with less side effects.